Cullinan Oncology Inc at Credit Suisse Healthcare Conference Transcript
Good morning. Thank you for attending the conference. Thank you, Jeff, for being here. Pleased to present our next speaker, Jeff, CFO of Cullinan Oncology, ticker CGEM, oncology focused. We'll see, I think, and hear more about some of the exciting and broad pipeline that they have and their strategic focus in this field. And so with that, I'll just pass to you, Jeff.
Thanks a lot, Eric. Appreciate it. So just before we begin, a quick note, what we're talking about today, we will have forward-looking statements. Investing in our securities involves risks. I would advise you to please consult with our 10-K and 10-Q to get a better understanding of the risk factors.
So yes, let me just pick up where Eric left off. So Cullinan Oncology, what are we all about?
First and foremost, we like to find high-impact targets in oncology. What do we mean by high impact? A target that's either involved in tumor cell proliferation and survival or targets that can really engender and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |